The neuropathologist at Mount Sinai and chief science officer of Precise Dx pairing spoke to the role of artificial intelligence in the diagnosis of diseases from peripheral tissue biopsies and its ability to improve neuropathology. [WATCH TIME: 8 minutes]
L. John Greenfield Jr, MD, PhD, “spoke” about the future of artificial intelligence in neurology with ChatGPT-4—one of the largest language modules that have grabbed the field’s interest.
The vice president of the Rare Disease Translational Center at the Jackson Laboratory provided commentary on the next steps needed to further understand stathmin-2’s role as a potential disease-modifying biomarker. [WATCH TIME: 3 minutes]
Although challenging, shared decision-making is a rewarding part of the practice of medicine. Involving patients in therapeutic decisions can improve patient autonomy and satisfaction—but it is not easy to implement.
The clinical associate professor of neurology at the University of Michigan spoke on the importance of sleep medicine education for trainees, as well as areas that could be improved. [WATCH TIME: 3 minutes]
This is the deck of the article. It can be used to provide further context to the headline and provides search engines with summary text for social posts.
The medical director of the Westport Headache Institute spoke to the role that devices can play in layered and variable treatment approaches, and how this better lends itself to offering personalized treatment to different individuals with migraine
The director of the Allegheny Multiple Sclerosis Treatment Center at Allegheny General Hospital discussed exploring the potential role of BTK inhibitors and advanced MRI techniques to address smoldering multiple sclerosis. [WATCH TIME: 10 minutes]
The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]
In this episode of MEDcast, expert neurologists delve into anti-CD20 disease modifying therapies (DMTs) in MS. They assess the correlation between clinical observations and immunological processes in MS patients, and also examine the role of the Epstein Barr virus in MS.
The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]
Caroline Just, MD, reflects on the challenges of diagnosing and treating rare neurological diseases, urging for improved education, collaboration, and research efforts.
A pair of cerebrovascular and neurosurgery experts discuss a novel approach to communicating hydrocephalus with an arachnoid granulation using a miniature implant, delivered via a percutaneous endovascular catheter.
The professor of medicine at the University of Manitoba detailed the implications of a new paper suggesting changes to the characterization of MS phenotypes and how it might impact previously approved therapies. [WATCH TIME: 3 minutes]
The chief development officer at Clene Nanomedicine provided insight on why CNM-Au8, an investigational agent in development, has shown positive results across both multiple sclerosis and ALS. [WATCH TIME: 2 minutes]
The assistant professor of neurology at Cleveland Clinic provided insight on the differences in ganglioside vs paranodal antibodies and their clinical use in various neuropathies. [WATCH TIME: 3 minutes]
The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.
The professor of neurology at Johns Hopkins Medicine provided an in-depth look at the 2022 RNDS and the unique design it offers patients with rare neuroimmune disorders. [WATCH TIME: 3 minutes]
The associate professor of clinical neurology at Weill Cornell Medicine discussed the progress made in multiple sclerosis in terms of expanding access to therapies and the challenges that persist for progressive forms of the disease in the field. [WATCH TIME: 10 minutes]
The division chief of neuromuscular disorders and vice-chair of research at Virginia Commonwealth University spoke to the ongoing success in the development of gene-mediated therapies and the challenges that come along with treating rare neuromuscular disease. [WATCH TIME: 3 minutes]
While shutdowns disrupted care for all patients with Parkinson disease, hospitals were forced to postpone elective procedures such as the initial DBS device implantation and implantable pulse generator replacements.
Standardizing protocols and incorporating objective diagnostics and telemedicine can enhance care for patients with PD and alleviate the burden on healthcare systems.
The vice president of medical affairs at SK Life Science talked about findings from a new post-hoc analysis which highlighted the importance of strategically reducing concomitant medications to minimize adverse events of epilepsy treatment. [WATCH TIME: 5 minutes]
Falls cost the US more than $50 billion annually, but platforms like CatchU, a transformative digital health tool, provide quantitative fall assessment that might significantly enhance the current standard of care for predicting falls.
The chief of neurology at Ascension Saint Agnes discussed the interventions her team implemented to improve patient-specific stroke discharge instructions.
A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.
The PhD student at Aarhus University provided insight on his study presented at 2022 ECTRIMS Congress on an innovative way using neuromuscular measures to discriminate those with MS at high risk for falls. [WATCH TIME: 2 minutes]
The co-CEOs and co-founders of Amylyx Pharmaceuticals discussed their immediate thoughts to the recent FDA AdComm meeting, which voted against evidence of efficacy for AMX0035 in ALS. [WATCH TIME: 3 minutes]
Ahmed Zayed Obeidat MD, PhD; Ravi Dukkipati, MD; and Gabriel Pardo, MD, FAAN, share key takeaways for clinicians treating RRMS.
Social determinants of health are conditions that people are born into and live under that affect their health, and can greatly impact clinical outcomes as well as contribute to health disparities and inequalities.